**REGISTERED COMPANY NUMBER: CE018092 (England and Wales) REGISTERED CHARITY NUMBER: 231708** Report of the Trustees and Financial Statements for the Year Ended 31 October 2023 for The Thalidomide Society Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW The Thalidomide Society Contents of the Financial Statements for the Year Ended 31 October 2023 |||Page|| |---|---|---|---| |Report of the Trustees|1|to|5| |Independent Examiner's Report||6|| |Statement of Financial Activities||7|| |Balance Sheet|8|to|9| |Notes to the Financial Statements|10|to|15| |Detailed Statement of Financial Activities|16|to|17| The Thalidomide Society for the Year Ended 31 October 2023 ## Report of the Trustees The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 October 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). ## **ACTING CHAIR'S STATEMENT** I am delighted to introduce the Thalidomide Society annual report for 2022/23: The last year has seen some big changes within our charity, not least being the departure of Ruth Blue as Secretary. Many of you will know that Ruth spent a considerable number of years as the Secretary and made great strides in raising the profile of the Thalidomide Society and building our ongoing legacy via the Thalidomide Stories Project that is now coming to its end and will be forwarded to the British Library for prosperity. We now welcome Julie Dixon who takes on the role of Administrator and we all look forward to working alongside Julie who brings a wealth of experience from the Charity world. It is always difficult when such an integral part of an organisation moves on. But I am sure you will join with me in welcoming Julie into our organisation and thanking Ruth for her years of dedication. The Society recognises that the last set of accounts has yet to be logged with the Charity Commission. This is due to the change in administration staff and the new administrator being unable to gain access to the Charity Commission site due to the Commissions new system of individuals having their own separate account. Our new administrator has asked on a number of occasions to be sent her new log in details to no avail. The Charity Commission has stated that it will note this and back date the logging of accounts. The HLF funded oral history has reached its conclusion and the project being forwarded to the British Library in early 2024. Which is good news. Moving forward I am excited to see what our new year brings. We are pushing ahead with our own project that is funded solely by the Society and its members. We will be updating and re-invigorating our website. This will give the Society more scope to inform others and tell our story. A vibrant website is our window. Though the year you will be receiving more updates via email and a second newsletter soon after the AGM. We will be planning a launch of the Thalidomide Stories Project for later in the year and much of the information will also be available on the website in due course. As you can see there is lots happening, and I am sure there is more to come. Let's keep driving the agenda to ensure our Legacy is available to as many people as possible. ## **OBJECTIVES AND ACTIVITIES** ## **Our Objectives** To assist in the relief of persons with impairments attributable to the effects of the drug known as thalidomide and other persons with similar impairments by: - Providing such persons, their families, and carers with opportunities to meet each other either in person or via - social media, at events and meetings organised by the Society. - Providing support and information to such persons, their families, and carers. - To advance the education of the public in the subject of the history of thalidomide by collecting, collating, - archiving, and preserving documents relating to the history of thalidomide and by undertaking or assisting in the - undertaking of educational and research projects concerning the effects of thalidomide and work of the Society and by publishing the useful results of such educational and research projects. In setting objectives and planning for activities the trustees have given due consideration to general guidance published by the Charity commission relating to public benefit including the guidance 'Public benefit: running a charity (PB2). Page 1 The Thalidomide Society Report of the Trustees for the Year Ended 31 October 2023 ## **OBJECTIVES AND ACTIVITIES** ## **Oral History Project - Thalidomide Stories** This project has been funded by Heritage Lottery Fund and is now complete and all documentation is with the Heritage Lottery Fund for review, this includes full accounts, expenditure receipts and spreadsheets, the project completion report, and the final project evaluation report. The digital files will be transferred to the British Library in February 2024. After this is complete, copyright and ownership of the project will be held jointly between the Thalidomide Society and the British Library. There is no fixed date yet for the when the project will become live at the British Library. The Thalidomide Society's parents' oral history project has not developed further over the past year, but it is hoped the British Library will accept it as well as the Thalidomide Stories, subject to the metadata creation. Our yearly AGM/Conference was held at St Georges Park, mainly due to them having a larger number of accessible rooms. It was an enjoyable event with good feedback from those attending. Giving opportunities for members to met up with old and new friends. We also gave the opportunity for members to attend via Zoom. Our Facebook page is well used and a great opportunity to share information with other members. We receive many inquiries, particularly from eighth and ninth graders from the USA, these young people chose to do their project for National History Day on thalidomide and their enthusiasm for understanding and knowledge is commendable. Presently our key areas of support are: - Information giving - Signposting to other services We presently produce one Newsletter a year for members, in this we can inform members of the yearly AGM/Conference outcomes, reproduce good news stories, remind people of initiatives, such as our Lottery. Our Thalidomide Society Lottery is an opportunity for people to donate to the Society, and this fund raising goes towards our projects. It is also a great opportunity to perhaps get a little gift back via our Lottery. ## **ACHIEVEMENT AND PERFORMANCE** ## **Investment Policy and Performance** At the year end the balance of the Society's investment portfolio was valued at £373,278 (2022 - £513,337) and generated income during the year of £16,729 (2022 - £22,125). The value of the investment portfolio significantly reduced because of market performance and disinvestments during the year for cashflow purposes. The Finance Committee actively monitors these investments. ## **FINANCIAL REVIEW** ## **Financial position** Total income for the year was £33,330 (2022 - £90,437). Expenditure for the year (excluding the investment movements) was £137,464 (2022 - £132,862). The total funds of the charity at the year end were £413,120 (2022 - £551,210). This consisted of unrestricted funds of £404,611 (2022 - £529,419) and restricted funds of £8,509 (2022 - £21,791). Page 2 The Thalidomide Society for the Year Ended 31 October 2023 ## Report of the Trustees ## **FINANCIAL REVIEW** ## **Restricted Funds** The restricted funds are accounted for separately. These funds are generated from several sources and are restricted for specific projects. These are: ## Support for Srey Hang Funds were generated from the Society's raffle and auctions at the AGM, as well as from occasional separate private donations and bequests. ## Oral History Project: Thalidomide Stories In July 2018 the Society was granted £96,935 of Heritage Lottery funding for Thalidomide Stories: An Oral History of Thalidomide Survivors. The funds will be used solely for this project. So far funding of £88,740 has been received, so far £96,803 has been spent on delivery of the project. ## Oral History Project: Parents' Oral History Funds generated from private bequests, net receipts from the Thalidomide Society Lottery, specific gifts from members and donations are used to support the Society's Parents' Oral History Project. Occasionally funds here too may be used to fund an interview with a thalidomide survivor or someone involved in the thalidomide community when it is needed for a specific talk or presentation on behalf of the Society. ## **Unrestricted Funds** The Society generates most of its unrestricted funds from its investment portfolio and uses this income to cover charitable activities and governance costs. ## **Reserves policy** Apart from the Restricted Funds, all reserves available for use by the Society are unrestricted and can be used for the Society in accordance with its charitable aims. The Trustees are aware the Society depends upon the income from its investments to fund its core activities and recognise the need to source other income to embark on any major projects. ## **FUTURE DEVELOPMENT** We will be moving forward with the Thalidomide Voices (part 2) Project that will run for two years and is funded by kind donations and Society lottery. Our website is being revamped, as we recognise that this is an essential window to people across the UK and further afield. We hope to develop some online friendship meetings. And will endeavour to send regular updates to members via email and produce a second newsletter each year, recognising the importance of communication. ## **STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document** The charity is controlled by its governing document, a CIO Association conversion dated 4 July 2019. ## **The Board of Trustees** The Board of Trustees is the overarching charity governors with delegated authority for the day-to-day management of all charity matters falling to the appointed Administrator. Our Trustee Board members oversee the charity's strategic direction and legal responsibilities. We welcome Sue Gooding to the board and two trustees have resigned. We look to appoint trustees that will enhance the Boards knowledge and enrich the charity. We employ one part-time administrator. With trustees sitting on selected sub-committees relating to Finance, Governance and Events. With one trustee being voted to line manage the administrator. Page 3 The Thalidomide Society for the Year Ended 31 October 2023 ## Report of the Trustees ## **STRUCTURE, GOVERNANCE AND MANAGEMENT** ## **Method of appointment or election of trustees** Charity management is the responsibility of the trustees elected or co-opted under the terms of the Constitution. The Board meets at least four times annually to regularly review strategy, budget, and performance. All trustees give their time voluntarily and receive no benefits from the charity. Potential conflicts of Interest are stated at the start of each meeting, ensuring transparency is maintained. All trustees receive relevant documentation. Trustees are encouraged to attend inexpensive and valid training courses as they arise. Former trustee Marie Pearse has continued to run the successful Lottery Project. ## **Risk management** The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. ## **REFERENCE AND ADMINISTRATIVE DETAILS** ## **Registered Company number** CE018092 (England and Wales) ## **Registered Charity number** 231708 ## **Registered office** The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW ## **Trustees** D Mansell (acting Chair from 23/01/2024, previously Vice Chair) M Argy R Bareham (resigned 28/09/2023) M de la Mare G Freeman S Gooding (appointed 15/05/2023) M Hogg D Tickell S Thakkar G Tweedy (resigned 04/03/2024) K West (Chair - resigned 23/01/2024) The following people are not trustees of the charity but hold the following positions: |Name|Position| |---|---| |Dr R Blue|Secretary to the Board of Trustees (until September 2023)| |J Dixon|Administrator to the Board of Trustees (from August 2023)| |J Tunbridge|Honorary Treasurer| Page 4 The Thalidomide Society for the Year Ended 31 October 2023 ## Report of the Trustees ## **REFERENCE AND ADMINISTRATIVE DETAILS** ## **Independent Examiner** Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW Approved by order of the board of trustees on ............................................. and signed on its behalf by: .......................................................................... Mr D Mansell - Trustee Page 5 ## Independent Examiner's Report to the Trustees of The Thalidomide Society ## **Independent examiner's report to the trustees of The Thalidomide Society ('the Company')** I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 October 2023. ## **Responsibilities and basis of report** As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act. ## **Independent examiner's statement** I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe: 1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or 4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)). I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. Mr Craig Alan Beale Lewis Smith & Co. Chartered Certified Accountants The Old Doctor's House 74 Grange Road Dudley West Midlands DY1 2AW Date: ............................................. Page 6 The Thalidomide Society ## Statement of Financial Activities ## for the Year Ended 31 October 2023 |Unrestricted
fund
Notes
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
90
Other trading activities
3
-
Investment income
4
16,681
Other income
13,910
**Total**
30,681
**EXPENDITURE ON**
**Charitable activities**
Staff costs
29,072
Other charges
84,461
Charitable activities
-
**Total**
113,533
Net gains/(losses) on investments
(33,956)
**NET INCOME/(EXPENDITURE)**
(116,808)
**Transfers between funds**
11
(8,000)
**Net movement in funds**
(124,808)
**RECONCILIATION OF FUNDS**
Total funds brought forward
529,419
**TOTAL FUNDS CARRIED FORWARD**
404,611|Restricted
funds
£
2,601
-
48
-
2,649
9,216
14,715
-
23,931
-
(21,282)
8,000
(13,282)
21,791
8,509|31.10.23
31.10.22
Total
Total
funds
funds
£
£
2,691
44,132
-
1,073
16,729
22,125
13,910
23,107
33,330
90,437
38,288
36,788
99,176
94,732
-
1,342
137,464
132,862
(33,956)
(27,542)
(138,090)
(69,967)
-
-
(138,090)
(69,967)
551,210
621,177
413,120
551,210| |---|---|---| The notes form part of these financial statements Page 7 The Thalidomide Society ## Balance Sheet ## 31 October 2023 |Unrestricted
fund
Notes
£
**CURRENT ASSETS**
Debtors
8
1,183
Investments
9
373,278
Cash at bank
32,676
407,137
**CREDITORS**
Amounts falling due within one year
10
(2,526)
**NET CURRENT ASSETS**
404,611
**TOTAL ASSETS LESS CURRENT**
**LIABILITIES**
404,611
**NET ASSETS**
404,611
**FUNDS**
11
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|Restricted
funds
£
-
-
8,509
8,509
-
8,509
8,509
8,509|31.10.23
Total
funds
£
1,183
373,278
41,185
415,646
(2,526)
413,120
413,120
413,120
404,611
8,509
413,120|31.10.22
Total
funds
£
1,183
513,337
40,676
555,196
(3,986)
551,210
551,210
551,210
529,419
21,791
551,210| |---|---|---|---| The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2023. The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2023 in accordance with Section 476 of the Companies Act 2006. The trustees acknowledge their responsibilities for - (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and - (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company. The notes form part of these financial statements continued... Page 8 The Thalidomide Society Balance Sheet - continued 31 October 2023 These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime. The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by: ............................................. Mr D Mansell - Trustee The notes form part of these financial statements Page 9 The Thalidomide Society Notes to the Financial Statements for the Year Ended 31 October 2023 ## **1. GENERAL INFORMATION** The Thalidomide Society is a Charitable Incorporated Organisation (CIO). Its principal activity is to work with thalidomide and similarly impaired people, their families and supporters, providing a social network for thalidomide and similarly impaired people. Its registered office is Flat 29, Weymouth House, Hill House Mews, Bromley, BR2 0DD ## **Company Status** The charity is a Charitable Incorporated Organisation (CIO). It is registered on Companies House with the company number CE018092 but is not required to submit and accounts or other documents with them. The company is registered with The Charity Commission with the charity number the 231708. It is required to file an annual report with them which includes a copy of these accounts. ## **2. ACCOUNTING POLICIES** ## **Basis of preparing the financial statements** The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention. ## **Income** All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. ## **Expenditure** Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure. ## **Taxation** The charity is exempt from corporation tax on its charitable activities. ## **Fund accounting** Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. ## **Pension costs and other post-retirement benefits** The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate. continued... Page 10 The Thalidomide Society Notes to the Financial Statements - continued for the Year Ended 31 October 2023 ## **2. ACCOUNTING POLICIES - continued** ## **Debtors** Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid. ## **Cash at bank and in hand** Cash at bank and in hand includes cash and short-term liquid investments with a short maturity of 3 months or less from the date of acquisition or opening of the deposit or similar account. ## **Liabilities** Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. ## **3. OTHER TRADING ACTIVITIES** ## **4.** ||31.10.23|31.10.22| |---|---|---| ||£|£| |Merchandise income|-|1,073| |**INVESTMENT INCOME**||| ||31.10.23|31.10.22| ||£|£| |Investment income|16,729|22,125| ## **5. TRUSTEES' REMUNERATION AND BENEFITS** There were no trustees' remuneration or other benefits for the year ended 31 October 2023 nor for the year ended 31 October 2022. ## **Trustees' expenses** During the year some trustees were paid expenses to cover travel costs. The amount of these payments made were £1,068 (2022 - £1,867). continued... Page 11 The Thalidomide Society ## Notes to the Financial Statements - continued for the Year Ended 31 October 2023 |**6.**|**STAFF COSTS**|||||| |---|---|---|---|---|---|---| |||||31.10.23||31.10.22| |||||£||£| ||Wages and salaries|||32,068||31,817| ||Social security costs|||-||(323)| ||Other pension costs|||1,084||1,516| |||||33,152||33,010| ||The average monthly number of employees during the year was|as follows:||||| |||||31.10.23||31.10.22| ||Employees|||2||2| ||No employees received emoluments in excess of £60,000.|||||| |**7.**|**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**|||||| |||Unrestricted||Restricted||Total| ||||fund|funds||funds| ||||£|£||£| ||**INCOME AND ENDOWMENTS FROM**|||||| ||Donations and legacies||36,588|7,544||44,132| ||Other trading activities||1,073||-|1,073| ||Investment income||22,117|8||22,125| ||Other income||23,107||-|23,107| ||**Total**||82,885|7,552||90,437| ||**EXPENDITURE ON**|||||| ||**Charitable activities**|||||| ||Staff costs||30,444|6,344||36,788| ||Other charges||93,572|1,160||94,732| ||Charitable activities||-|1,342||1,342| ||**Total**|124,016||8,846||132,862| ||Net gains/(losses) on investments||(27,542)||-|(27,542)| ||**NET INCOME/(EXPENDITURE)**||(68,673)|(1,294)||(69,967)| ||**RECONCILIATION OF FUNDS**|||||| ||Total funds brought forward|598,092||23,085||621,177| ||**TOTAL FUNDS CARRIED FORWARD**|529,419||21,791||551,210| continued... Page 12 The Thalidomide Society |Notes to the Financial Statements-continued
for the Year Ended 31 October 2023
**8.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
PAYE & NI debtor
**9.**
**CURRENT ASSET INVESTMENTS**
Listed investments
**10.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Pension creditor
Accruals and deferred income
**11.**
**MOVEMENT IN FUNDS**
At
1.11.22
£
**Unrestricted funds**
General fund
529,419
**Restricted funds**
Thalidomide Society Oral History
10,898
Support for Srey Hang
4,556
HLF
6,337
21,791
**TOTAL FUNDS**
551,210|
Net
movement
in funds
£
(116,808)
2,608
39
(23,929)
(21,282)
(138,090)||31.10.23
£
1,183
31.10.23
£
373,278
31.10.23
£
78
2,448
2,526
Transfers
between
funds
£
(8,000)
-
-
8,000
8,000
-||31.10.22
£
1,183
31.10.22
£
513,337
31.10.22
£
391
3,595
3,986
At
31.10.23
£
404,611
13,506
4,595
(9,592)
8,509
413,120| |---|---|---|---|---|---| ||||||| continued... Page 13 The Thalidomide Society Notes to the Financial Statements - continued for the Year Ended 31 October 2023 ## **11. MOVEMENT IN FUNDS - continued** Net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
**Restricted funds**
Thalidomide Society Oral History
Support for Srey Hang
HLF
**TOTAL FUNDS**
**Comparatives for movement in funds**
**Unrestricted funds**
General fund
**Restricted funds**
Thalidomide Society Oral History
Support for Srey Hang
Srey Hang & Beyond
HLF
**TOTAL FUNDS**|Incoming
resources
£
30,681
2,608
39
2
2,649
33,330|Resources
expended
£
(113,533)
-
-
(23,931)
(23,931)
(137,464)
At
1.11.21
£
598,092
3,760
1,341
4,555
13,429
23,085
621,177|Gains and
Movement
losses
in funds
£
£
(33,956)
(116,808)
-
2,608
-
39
-
(23,929)
-
(21,282)
(33,956)
(138,090)
Net
movement
At
in funds
31.10.22
£
£
(68,673)
529,419
7,138
10,898
(1,341)
-
1
4,556
(7,092)
6,337
(1,294)
21,791
(69,967)
551,210| |---|---|---|---| continued... Page 14 The Thalidomide Society Notes to the Financial Statements - continued for the Year Ended 31 October 2023 ## **11. MOVEMENT IN FUNDS - continued** Comparative net movement in funds, included in the above are as follows: |**Unrestricted funds**
General fund
**Restricted funds**
Thalidomide Society Oral History
Support for Srey Hang
Srey Hang & Beyond
HLF
**TOTAL FUNDS**|Incoming
resources
£
82,885
7,546
-
2
4
7,552
90,437|Resources
expended
£
(124,016)
(408)
(1,341)
(1)
(7,096)
(8,846)
(132,862)|Gains and
Movement
losses
in funds
£
£
(27,542)
(68,673)
-
7,138
-
(1,341)
-
1
-
(7,092)
-
(1,294)
(27,542)
(69,967)| |---|---|---|---| ## **12. RELATED PARTY DISCLOSURES** There were no related party transactions for the year ended 31 October 2023. Page 15 The Thalidomide Society |Detailed Statement of Financial Activities||| |---|---|---| |for the Year Ended 31 October 2023||| ||31.10.23|31.10.22| ||£|£| |**INCOME AND ENDOWMENTS**||| |**Donations and legacies**||| |Donations|1,191|42,587| |Lottery income|1,500|1,545| ||2,691|44,132| |**Other trading activities**||| |Merchandise income|-|1,073| |**Investment income**||| |Investment income|16,729|22,125| |**Other income**||| |Delgate fees|13,910|23,107| |**Total incoming resources**|33,330|90,437| |**EXPENDITURE**||| |**Charitable activities**||| |Grants to institutions|-|1,342| |**Support costs**||| |**Human resources**||| |Wages|32,068|31,817| |Social security|-|(323)| |Pensions|1,084|1,516| |Travel and subsistence costs|5,136|3,778| ||38,288|36,788| |**Other**||| |Insurance|254|254| |Telephone and communications|726|3,204| |Postage and stationery|260|193| |Computer and IT expenses|1,677|2,601| |Training seminars & workshops|78,207|84,492| |Oral history photography costs|7,946|-| |Oral history transcribing costs|4,243|-| |Repairs and renewals|1,198|179| |Recruitment costs|633|-| |Carried forward|95,144|90,923| This page does not form part of the statutory financial statements Page 16 The Thalidomide Society ## Detailed Statement of Financial Activities for the Year Ended 31 October 2023 |Detailed Statement of Financial Activities
for the Year Ended 31 October 2023||| |---|---|---| ||31.10.23|31.10.22| ||£|£| |**Other**||| |Brought forward|95,144|90,923| |Investment fees|1,137|1,017| |Accountancy fees|2,034|1,920| |Legal fees|861|872| ||99,176|94,732| |Total resources expended|137,464|132,862| |**Net expenditure before gains and losses**|(104,134)|(42,425)| |**Realised recognised gains and losses**||| |Realised gains/(losses) on fixed asset investments|(33,956)|(27,542)| |**Net expenditure**|(138,090)|(69,967)| This page does not form part of the statutory financial statements Page 17